PMID- 29516989
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20220330
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 14
IP  - 1
DP  - 2018 Jan
TI  - Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma.
PG  - 220-225
LID - 10.4103/0973-1482.193125 [doi]
AB  - AIMS: The prognosis of cholangiocarcinoma (CCA) is generally poor because there 
      is a lack of effective diagnostic tools including laboratory assessments and 
      imageological examination. Therefore, a novel biological marker (biomarker) to 
      effectively diagnose cancer is highly desirable in clinical. Previously, serum 
      microRNAs as biomarkers of cancers have been reported. However, it was still 
      unclear about the clinical significance of serum microRNA-21 (miR-21) expression 
      levels for CCA. MATERIALS AND METHODS: The serum samples were separately 
      collected from fifty patients of CCA, 15 patients of hepatolithiasis, and 15 
      healthy volunteers; quantitative real-time polymerase chain reaction was used for 
      measuring miR-21 expression level in serum. The clinicopathological data were 
      recorded before patients discharged. RESULTS: In the CCA serum, the expression 
      level of miR-21 significantly upregulated (P < 0.05). With the tumor, node, and 
      metastasis stage developed (Stage I vs. III and IV, P < 0.05), the serum miR-21 
      expression level increased, but there was no statistical difference between Stage 
      I patients and hepatolithiasis patients or healthy control (P > 0.05 for both). 
      Furthermore, the miR-21 level was significant difference between pre- and 
      post-operative serum (P < 0.05) for the high miR-21 expression group. The serum 
      miR-21 expression levels were defective in discriminating patients with CCA from 
      healthy control subjects by receiver-operator curve analysis because the area 
      under the curve (AUC) value was 0.871 which was not better than the conventional 
      CCA markers-carbohydrate antigen 19-9 (AUC value = 0.96). However, in serum, high 
      expression level miR-21 was significantly related to clinical stage, invasion 
      depth, lymph vessel infiltration, metastasis status, differentiation status, 
      whether to resection, and poor survival of CCA patients (P < 0.05 for all). 
      CONCLUSIONS: This study suggested that serum miR-21 was a promising biomarker for 
      diagnosing the late stage CCA and would have potential to be a useful prognostic 
      biomarker of CCA.
FAU - Liu, Chen-Hai
AU  - Liu CH
AD  - Shandong University, Jinan 250012, Shandong, China.
FAU - Huang, Qiang
AU  - Huang Q
AD  - Department of General Surgery, Anhui Provincial Hospital, Anhui Key Laboratory of 
      Hepatopancreatobiliary Surgery, Hefei 230001, Anhui, China.
FAU - Jin, Zhi-Yuan
AU  - Jin ZY
AD  - Department of General Surgery, Anhui Provincial Hospital, Anhui Key Laboratory of 
      Hepatopancreatobiliary Surgery, Hefei 230001, Anhui, China.
FAU - Xie, Fang
AU  - Xie F
AD  - Department of General Surgery, Anhui Provincial Hospital, Anhui Key Laboratory of 
      Hepatopancreatobiliary Surgery, Hefei 230001, Anhui, China.
FAU - Zhu, Cheng-Lin
AU  - Zhu CL
AD  - Department of General Surgery, Anhui Provincial Hospital, Anhui Key Laboratory of 
      Hepatopancreatobiliary Surgery, Hefei 230001, Anhui, China.
FAU - Liu, Zhen
AU  - Liu Z
AD  - Department of General Surgery, Anhui Provincial Hospital, Anhui Key Laboratory of 
      Hepatopancreatobiliary Surgery, Hefei 230001, Anhui, China.
FAU - Wang, Chao
AU  - Wang C
AD  - Department of General Surgery, Anhui Provincial Hospital, Anhui Key Laboratory of 
      Hepatopancreatobiliary Surgery, Hefei 230001, Anhui, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Circulating MicroRNA)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bile Duct Neoplasms/blood/diagnosis/*genetics/*mortality
MH  - *Biomarkers, Tumor
MH  - Cholangiocarcinoma/blood/diagnosis/*genetics/*mortality
MH  - *Circulating MicroRNA
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prognosis
OTO - NOTNLM
OT  - Biological markers
OT  - cholangiocarcinoma
OT  - microRNA-21
OT  - serum
COIS- There are no conflicts of interest.
EDAT- 2018/03/09 06:00
MHDA- 2018/08/31 06:00
CRDT- 2018/03/09 06:00
PHST- 2018/03/09 06:00 [entrez]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
AID - JCanResTher_2018_14_1_220_193125 [pii]
AID - 10.4103/0973-1482.193125 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2018 Jan;14(1):220-225. doi: 10.4103/0973-1482.193125.